Zhao Yan New Drug rises over 4% amid CRO sector rally

Zhao Yan New Drug (6127.HK) climbed 4.15% in Hong Kong trading to HK$25.520.

The rise followed a broader rally in the A-share CRO sector. Market attention has also focused on surging lab monkey prices, which are expected to boost earnings for CRO firms holding relevant biological assets. Zhao Yan New Drug anticipates a significant increase in net profit for the first half of the year, driven primarily by the appreciation of its biological assets.